Testing an experimental drug OPN-6602 for advanced multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests an experimental oral drug called OPN-6602 for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The main goal is to see if the drug is safe and tolerable, and to find the best dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of multiple myeloma (a cancer of plasma cells in the bone marrow).
- Your myeloma has come back or stopped responding to at least 3 different prior treatments, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.
- You are not a candidate for or cannot tolerate other treatments that are known to help.
- Your blood counts, kidney, liver, and heart function need to be within a certain healthy range.
- You cannot have certain other conditions such as active plasma cell leukemia, POEMS syndrome, or a history of Stevens Johnson syndrome.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two approved drugs (lenalidomide and dexamethasone) plus an experimental drug (iberdomide) for people with multiple myeloma that has returned or stopped responding to treatment. It aims to see if this new combination can help control the disease.
This trial tests a new combination of three drugs—inobrodib, pomalidomide, and dexamethasone—for people with multiple myeloma that has come back or stopped responding to treatment. The goal is to see if this new drug adds benefit for patients who have tried other therapies.
This trial tests a new injected drug for people with multiple myeloma that has returned or stopped responding to at least 3 prior treatments. The goal is to see if the drug is safe and works against the cancer.
This trial tests an experimental drug called JNJ-79635322 for people with multiple myeloma that has come back or hasn't responded to at least three previous treatments, including a PI, an IMiD, and a CD38-targeted antibody. The goal is to see if this new drug can help control the disease.
This trial tests a new drug called CM336 for people with multiple myeloma that has come back or stopped responding to at least two previous treatments. It aims to see if CM336 can help control the disease.
This trial tests a new treatment called OL-101 for people whose multiple myeloma has come back or stopped responding to at least three prior treatments, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody. It aims to see if OL-101 can help control the disease.
Hear when a new Relapsed Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.